Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ji Xing In-licenses China Rights to Eye Drop Therapies for Far-Sightedness

publication date: Apr 13, 2022

Shanghai Ji Xing Pharma in-licensed Greater China rights for two eye-drop far-sightedness therapies from San Diego’s Lenz Therapeutics in a $110 million pact. Lenz’s two therapies are based on aceclidine, a small molecule acetylcholine receptor agonist that causes pupil contraction (miosis), creating a pinhole effect that improves near vision. Ji Xing is backed by New York’s RTW Investments, which invested $10 million in Lenz. Ji Xing will pay $15 million upfront and up to $95 million in milestones, plus royalties. Lenz plans to start US Phase III trials of the two presbyopia therapies in H2 of 2020. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital